US › Healthcare

Sol Gel Technologies Ltd (SLGL)

US · Healthcare · Biotechnology

$64.25-6.48%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

$591,000

Revenue YoY

-96.6%

Net profit

$-3.7M

Profit YoY

-131.7%

EPS

$-1.13

EPS estimate

$-2.31

Net margin

-622.8%

EPS came in at -1.13 against a street estimate of -2.31 — a beat of 51.1%.

Key statistics

Market cap

$227.5M

Forward P/E

9.3

P/B

4.10

Book value

$14.69

EPS (TTM)

$-5.61

52-week high

$97.97

52-week low

$28.81

50-day MA

$72.55

200-day MA

$73.10

Beta

1.15

Analyst view

Analysts rate Sol Gel Technologies Ltd a strong buy (3 buy, 0 hold, 0 sell out of 3) with an average price target of $152.50.

Shareholding

Insiders

59.66%

Institutions

43.06%

Largest institutional holders

Fund	Stake
Opaleye Management Inc	17.95%
Great Point Partners LLC	9.85%
Phoenix Financial Ltd	5.25%
Trails Edge Capital Partners, LP	5.00%
Affinity Asset Advisors, LLC	3.05%
Squadron Capital Management LLC	1.87%
Citadel Advisors Llc	1.17%
Gilder Gagnon Howe & CO LLC	0.81%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Sol Gel Technologies Ltd — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-19.